-+ 0.00%
-+ 0.00%
-+ 0.00%

Morgan Stanley Upgrades Nurix Therapeutics to Overweight, Raises Price Target to $36

Benzinga·01/08/2026 12:10:16
Listen to the news
Morgan Stanley analyst Terence Flynn upgrades Nurix Therapeutics (NASDAQ:NRIX) from Equal-Weight to Overweight and raises the price target from $15 to $36.